Company Information
CIN
Status
Date of Incorporation
31 May 1985
State / ROC
Ahmedabad / ROC Ahmedabad
Last Balance Sheet
31 March 2023
Last Annual Meeting
31 July 2023
Paid Up Capital
1,147,695,490
Authorised Capital
1,754,667,520
Directors
Binish Hasmukh Chudgar
Director/Designated Partner
about 2 years ago
about 2 years ago
Ratnasami Venkatesh
Director/Designated Partner
about 2 years ago
about 2 years ago
Archana Ravindrarai Dholakia
Director/Designated Partner
over 2 years ago
over 2 years ago
Jayesh Shantilal Shah
Director/Designated Partner
over 2 years ago
over 2 years ago
Nimish Hasmukh Bhai Chudgar
Director/Designated Partner
over 2 years ago
over 2 years ago
Sanjay Kukreja
Director/Designated Partner
over 2 years ago
over 2 years ago
Tilokchand Punamchand Ostwal
Director/Designated Partner
almost 3 years ago
almost 3 years ago
Surender Kumar Tuteja
Director/Designated Partner
almost 3 years ago
almost 3 years ago
Tushar Dhansukh Shroff
Manager/Secretary
over 6 years ago
over 6 years ago
Urmish Hasmukh Chudgar
Director/Designated Partner
about 29 years ago
about 29 years ago
Past Directors
Kusumben Hasmukhbhai Chudgar
Additional Director
over 10 years ago
over 10 years ago
Hasmukh Chudgar
Whole Time Director
over 11 years ago
over 11 years ago
Ajit Rasiklal Sanghvi
Additional Director
almost 15 years ago
almost 15 years ago
John Geoffrey Goddard
Additional Director
almost 15 years ago
almost 15 years ago
Nitin Ram Potdar
Additional Director
almost 15 years ago
almost 15 years ago
Rutul Jayantkumar Shukla
Company Secretary
over 19 years ago
over 19 years ago
Patents
The present invention is directed to a stable veterinary phosphorous composition wherein the said composition comprises of a phosphorous source, an inosine source and a pyruvate source and has improved physical stability. Also disclosed is a process for the preparation of the said injectable composition. The composi...
The present application relates to process for preparation R-(+)-N-propargyl-l-aminoindane also known as rasagiline and its pharmaceutically acceptable salts.
This present invention relates to pharmaceutical compositions comprising fixed dose combinations of capecitabine and cyclophosphamide, processes for the preparation thereof, and their use to treat cancer diseases.
The present invention relates to an apparatus to administer an enema comprising: an enema bag, wherein the enema bag includes an opening, a delivery tube, an applicator nozzle and a removable cap. The tube has two ends, wherein the one end is attached in the opening of the enema bag and on the other end applicator n...
The present invention relates in a novel process for lhe preparation of Soralcnib Tosylate Form III from Sorafenib Tosylate Elhanol Solvate.
The present invention relates to a mucoadhesive tablet comprising pregabalin with at least one mucoadhesive excipient, at least one swelling agent and at least one gelling agent, wherein the mucoadhesive tablet maintains gastric retention for the time period during which the drug is released into the stomach. Furthe...
The present invention provides a stable, absolutely ethanol free, composition of docetaxel to prevent the patient from alcoholic intoxication or anaphylactic shock further this invention also describes the process for preparation of stable composition of docetaxel.
The present invention provides novel a crystalline form of Endoxifen citrate and process for preparation thereof.
The present invention relates to a modified release tablet comprising pregabalin with at least one low-density excipient, at least one swelling agent and at least one gelling agent, wherein the modified release tablet substantially maintains its hydrodynamic balance and physical integrity for the time period during ...
The present invention relates to a bilayer pharmaceutical composition comprising: a first layer of sustained-release bupropion or its pharmaceutically acceptable salts and a second layer of sustained-release naltrexone or its pharmaceutically acceptable salts, with pharmaceutically acceptable excipients for the trea...
The present invention relates to a layered pharmaceutical composition comprising: a first layer of sustained-release bupropion or its pharmaceutically acceptable salts, a second layer of sustained-release naltrexone or its pharmaceutically acceptable salts, with pharmaceutically acceptable excipients, and an interme...
The present invention relates to an improved process for the preparation of sorafenib tosylate, Sorafenib tosylate is 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl] carbamoyl amino]phenoxy]-N-methyl-pyridine-2-carboxamide tosylate of following formula:
The present invention relates to a stable transdermal gel composition comprising Testosterone, a penetration enhancer, a gelling agent with pharmaceutically acceptable excipients. Further, the invention relates to the method of administering the said transdermal gel and its uses thereof.
The present invention relates to a liquid pharmaceutical composition comprising a conjugated erythropoietin, buffer, sugar, tonicity modifier and amino acid as an aggregation inhibitor. More preferably the present invention provides a stable pharmaceutical composition which encompasses conjugated erythropoietin comp...
The present invention relates to novel and thermostable lyophilized pharmaceutical composition of Romiplostim (Fc-peptide fusion protein) along with buffer, bulking agent, stabilizer, and surfactant at pH range of 4.0-6.0.
The present invention relates to an improved process for preparation of vildagliptin of following formula (I)
Formula (I)
The present invention also relates to a process for preparation of compound of formula (II)
Formula (II)
The present invention relates to a novel and user compliant nasal irrigation device (10) for continuous and constant delivery of the drug solution or nasal irrigation solution under pressure for rinsing the nasal passage and alleviating the allergies and infections associated with nasal passage. Further, the present...
The invention relates to novel crystalline form of O-desmethylvenlafaxine and a process for its preparation. The crystalline form of O-desmethylvenlafaxine of the present invention can be used for the manufacture of pharmaceutical compositions for the treatment of depression.
The present invention provides novel process for preparation of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one, commonly known as perampanel having the formula I. The present invention also provides novel intermediate compound of formula VI and process for the preparation of intermediate compound ...
The present invention relates to an improved process for the preparation of dofetilide and intermediates thereof. Dofetilide is N-[4-(2-[2-[4-(Methanesulphonamido)phenoxy]-N-methylethylamino]ethyl)phenyl]methanesulphonamide of following formula:
The present invention relates to a stable non-aqueous pharmaceutical composition comprising bendamustine or a pharmaceutically acceptable salt thereof, with suitable pharmaceutically acceptable excipients. Further it relates to a process for the preparation of the said composition and uses thereof.
...
The present invention relates to a stable topical gel composition comprising Tolfenamic acid with pharmaceutically acceptable excipients. Further, the invention relates to the process for the preparation of the said stable topical gel composition and its uses thereof.
The present invention relates to oral veterinary compositions comprising nutritional components such as calcium, phosphorus and vitamins for the treatment and/or maintenance of animal health. Further the invention relates to the process for preparation of the said compositions.
A Method For Preparation Of N (3 Ethynylphenyl) 6,7 Bis(2 Methoxyethoxy)quinazolin 4 Amine And Salts
Provided herein is a process to prepare erlotinib hydrochloride; also the novel salts of erlotinib and process for preparation thereof.
The present invention relates to novel process for preparation of amorphous apremilast.
The present invention provides a novel process for preparation of choline fenofibrate of formula
(III).
The present application relates to process for preparation and purification of decitabine.
The present invention relates to a stable tablet-in-tablet pharmaceutical composition comprising fixed dose combinations of cyclophosphamide and capecitabine and one or more pharmaceutically acceptable excipient, process for the preparation thereof, and their use in treating cancer diseases.
The present invention relates to an extended release capsules comprising multiple units of Capecitabine, wherein the dissolution of Capecitabine from the said composition is extended up to 12 hours. Further the present invention discloses process for the preparation of the said composition.
The present invention relates to a stable Carfilzomib Injection comprising Carfilzomib or pharmaceutically acceptable salts thereof with pharmaceutically acceptable excipients that substantially increase the solubility and wherein the injection is free from cyclodextrin derivatives.
The present invention provides a novel process for preparation of anagliptin of formula I. The invention also provides polymorphs of anaglitpin of formula I and process for the preparation thereof.
The present invention relates to Ranibizumab cloning, expression and production using a novel approach for better yield and biologically active protein.
Disclosed herein is an improved and efficient process for preparation of fesoterodine and its pharmaceutically acceptable salt. Disclosed also herein is novel intermediate of formula (III). Also disclosed are metal salts of formula (XII) and preparation thereof-
The present invention relates to extended release tablets comprising Capecitabine, wherein the dissolution of Capecitabine from the said tablets is extended up to at least 12 hours. Further, the present invention discloses process for the preparation of the said tablets.
Disclosed herein is a process for preparation of lapatinib and novel intermediates
thereof.
Provided herein is process for preparation of choline fenofibrate. The process includes reaction of fenofibric acid with choline chloride in presence of non-metallic inorganic base.
Provided herein is a process for preparation agomelatine and purification.
This present invention relates to pharmaceutical composition comprising fixed dose combination of linagliptin and metformin HCl wherein the composition is devoid of any basic amino acids. Further this invention also relates to process for the preparation of said composition & use of the said composition in treatment...
The present invention relates to a novel process for preparation of cabazitaxel (1) starting from 10-Deacetyf baccatin or derivative that involves methylation of 7,10 -OH groups. Also provided is a novel process using chiral bis-lactam linker for the synthesis of cabazitaxel
The present invention discloses a gel formulation of aceclofenac alone or in combination with ingredient which act as anti-inflammatory agent and its process for preparation wherein aceclofenac is aceclofenac or its pharmaceutically acceptable salts or derivatives.
Present invention relates to novel pharmaceutical composition of Rasagiline mesylate wherein the said pharmaceutical composition has desired bioavailability. Further, the present invention also discloses process for the preparation of the said pharmaceutical composition of Rasagiline mesylate.
...
NOT APPLICABLE.
The present invention discloses a process for preparation of O-desmethylvenlafaxine. The process comprises use of mercapto carboxyiic acid as demethylating agent.
The invention is directed to a stable injectable ready-to-use (RTU) aqueous fludarabine phosphate composition. Fludarabine phosphate composition of the present invention comprises of fludarabine phosphate, a buffer and water for injection. Fludarabine phosphate composition of the present invention is stable against ...
The present invention relates to a stable injectable composition of Topotecan or its pharmaceutically acceptable salts wherein the pH of the composition is below 3.0. Further, the invention discloses process for the preparation of the said stable injectable composition of Topotecan.
The present invention provides a process for the preparation of eslicarbazepine and rlicarbazepine and their acetates by resolution of racemic licarbazepine using acetyl mandelic acid.
The present invention relates to stable; ready to use injectable benzodiazepine composition of Olanzapine or its pharmaceutically acceptable salt and process for preparation thereof.
The present invention relates to an extended release composition of paliperidone for oral administration comprising paliperidone and at least one matrixing agent. The said extended release composition maintains desired therapeutic drug effect over a prolonged period of time and thereby reduces the side effects resul...
Provided herein is a process to prepare lacosamide, comprising O-methylation in presence of methylating agent, base and solvent.
Provided herein is process for preparation of rivaroxaban and intermediates thereof.
Provided herein is a process for the preparation of trazodone or pharmaceutically acceptable salts thereof, in high yield and purity. Provided further is process for the preparation of trazodone intermediate.
The present invention relates to a composition of Tolfenamic acid for oral administration, wherein the composition is devoid of surfactant, solubilizer or any other means of solubility enhancement. The said composition when dispensed as an oral dosage form provides effective dissolution of Tolfenamic acid. Further, ...
This present invention relates to extended release pharmaceutical composition of highly soluble active pharmaceutical substances comprising a drug matrix core containing the said active substance and non-swelling pH independent release retardant, and the said drug matrix core further comprises a functional coat, wit...
The present invention relates to a liquid pharmaceutical composition comprising an anti-TNFa antibody, buffer, stabilizer, and surfactant.
The present invention relates to a pharmaceutical composition comprising vilazodone hydrochloride, wherein the blend uniformity of the said composition is between 95% and 105%. Further it relates to the process for the preparation of the said composition and uses thereof.
The present invention relates to an improved process for the preparation of Mirabegron and its intermediates. Mirabegron is chemically described as 2-(2-aminothiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl] acetamide. It has the structure of formula I.
...
The present invention relates to a pharmaceutical composition comprising Apremilast with at least one rate-controlling polymer. The present invention provides an immediate release composition comprising amorphous form of apremilast, wherein the drug release from the tablet is controlled by a rate-controlling polymer...
The present invention relates to a pharmaceutical composition of Capecitabine, wherein the said composition comprises of immediate release Capecitabine and extended release Capecitabine. Further the present invention discloses process for the preparation of the said composition.
The present invention relates to pharmaceutical composition comprising Everolimus and hot melt extrusion (HME) grade hydroxypropyl methylcellulose, and process for the preparation of the said composition.
“A stable ready to use pharmaceutical composition of Levothyroxine”
ABSTRACT
The present invention relates to a stable, ready to use, injectable pharmaceutical composition comprising Levothyroxine or a pharmaceutically acceptable salt thereof, a buffer selected from a group of leucine or glycine and other phar...
“A Stable Formulation of Cetrorelix”
ABSTRACT
The present invention relates to a stable formulation of Cetrorelix or its pharmaceutically acceptable salt in the form of ready-to-use solution. The said stable ready-to-use solution of Cetrorelix prevents gel formation and provides better patient compliance. Furt...
“Pharmaceutical composition of Temozolomide.”
ABSTRACT
The present invention relates to the stable pharmaceutical composition of temozolomide for oral administration. The said pharmaceutical composition is in the form of powder for oral suspension, wherein the said powder is reconstituted with a liquid vehic...
“Pharmaceutical composition of imatinib.”
ABSTRACT
The present invention relates to a pharmaceutical composition comprising imatinib or its pharmaceutically acceptable salt thereof and one or more pharmaceutical acceptable excipients in powder form, which can be reconstituted with a diluent just before admin...
“Stable Oral Composition of Cyclophosphamide”
ABSTRACT
The present invention relates to a stable oral composition for cyclophosphamide or its pharmaceutically acceptable salt. The said composition for cyclophosphamide can be in the form of powder for oral solution, which can provide an improved stability, ease...
“Naltrexone formulation.”
ABSTRACT
The present invention related to lactose free, stable pharmaceutical composition comprising naltrexone or its pharmaceutically acceptable salt thereof. Further, the present invention provides process for the preparation of the said composition and its use for the treatment ...
“Stable topical pharmaceutical composition”
ABSTRACT
The present invention provides a stable topical pharmaceutical composition comprising 5-Fluorouracil and Calcipotriol or pharmaceutically acceptable salts thereof, for use in the treatment of actinic keratosis and other skin diseases. Further, the present in...
“Liquid Melphalan Composition.”
ABSTRACT
The present invention related to a stable liquid pharmaceutical composition comprising melphalan or its pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients, wherein the said stable liquid pharmaceutical composition is first ...
The present invention relates to an improved process for preparation of carmustine (I).
The present invention also relates to preparation of 1,3-bis(2-chloroethyl)urea (II)
an intermediate used in preparation of carmustine.
The present invention relates to an extended release pharmaceutical composition of Clozapine. The present invention provide an extended release pharmaceutical composition comprising Clozapine, a seal coating, an acidic coating, and an extended release coating. The invention is particularly suitable for dispensing a ...
“Non-pulsatile prolonged-release betahistine oral solid compositions”
ABSTRACT
The present invention relates to an oral solid non-pulsatile 24 hours prolonged-release composition comprising an amount of betahistine, or of a pharmaceutically acceptable salt thereof, equivalent to 48 mg of betahistine dihydrochl...
The present invention relates to a pharmaceutical composition comprising Efinaconazole that are useful in the treatment of fungal infections. Such compositions can be given by topical administration such that it can enhance drug penetration for effective treatment of fungal diseases of the nail or nail bed. Further ...
IMPROVED PURIFICATION METHOD OF RECOMBINANT PTH (1-34)
ABSTRACT
The present invention relates to improved method for purification of recombinant PTH (1-34) with decreased protein precipitation or particle formation.
“Stable lyophilized composition of Cyclophosphamide”
ABSTRACT
This present invention relates to a stable lyophilized composition of Cyclophosphamide. The said stable lyophilized composition of Cyclophosphamide provides an improved moisture content than the lyophilized Cyclophosphamide compositions obtained by ...
“Stable non-aqueous injectable pharmaceutical composition”
ABSTRACT
The present invention relates to a stable non-aqueous injectable pharmaceutical composition of progesterone or its derivatives, wherein the said pharmaceutical composition comprises of benzyl benzoate and polyethylene glycol. Further, the pres...
The present invention relates to a stable non-aqueous pharmaceutical composition comprising a hydrophobic drug or a pharmaceutically acceptable salt thereof, involving cyclodextrin and propylene glycol. The present invention can be used as a ready-to-use composition or a ready-to-dilute composition without the need ...
“Pharmaceutical Composition of Pirfenidone.”
ABSTRACT
The present invention relates to a pharmaceutical composition comprising pirfenidone, copovidone and one or more pharmaceutically acceptable excipients. It further provides a process for the preparation of said pharmaceutical composition, and their use to...
“PROCESS FOR PREPARATION OF BRIVARACETAM”
The present invention relates to an improved process for preparation of brivaracetam (I).
The present invention also relates to novel intermediates useful in the preparation of brivaracetam.
“Pharmaceutical composition of Nintedanib esylate”
ABSTRACT
The present invention provides a pharmaceutical composition comprising suspension of Nintedanib esylate and lauroyl polyoxyl-6 glyceride or hydrogenated vegetable oil, in a soft gelatin capsule; wherein lauroyl polyoxyl-6 glyceride or hydrogenated veg...
“A stable, ready to use aqueous pharmaceutical composition of Pemetrexed”
ABSTRACT
The present invention provides a stable, ready to use aqueous parenteral composition comprising Pemetrexed, wherein the composition comprises Pemetrexed disodium, mixture of antioxidants and pharmaceutically acceptable excipient...
“A process for preparation of a stable pharmaceutical composition of Bortezomib”
ABSTRACT
The present invention relates to a process for preparation of a stable pharmaceutical composition of Bortezomib. The said pharmaceutical composition of Bortezomib provides an improved stability compared to the reconstitut...
“PROCESS FOR PREPARATION OF APREMILAST CRYSTALLINE FORM A AND INTERMEDIATE THEREOF”
ABSTRACT
The present invention relates to an improved process for preparation of crystalline Form A of apremilast (I) and intermediate of formula (IV).
(I)
(IV)
“Pharmaceutical composition comprising HMG-CoA reductase inhibitors and Fenofibrate”
ABSTRACT
The present invention provides a multilayer, pharmaceutical composition comprising a fixed dose combination of rosuvastatin or a pharmaceutically acceptable salt thereof and fenofibrate or a pharmaceutically acceptabl...
PROCESS FOR PREPARATION OF TOFACITINIB AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
ABSTRACT
The present invention relates to an improved process for preparation of tofacitinib (I) and pharmaceutically acceptable salt thereof.
(I)
PURIFICATION OF ADALIMUMAB USING TANDEM CHROMATOGRAPHY
ABSTRACT
The present invention provides a novel process for the purification of Adalimumab obtained from a fermentation harvest of CHO cell culture expressing said Adalimumab. The present invention further provides a novel purification process of Adalimumab...
“Oral Suspension of Capecitabine”
ABSTRACT
The present invention relates to a new dosage form of Capecitabine in form of suspension for oral administration. Further, the present invention discloses process for the preparation of the said suspension.
PROCESS FOR PREPARATION OF RECOMBINANT ADENO-ASSOCIATED VIRUS PARTICLE
The present invention relates to the consistent and reproducible method for process scale up and improving yield of AAV production. Further, present invention relates to downstream purification process for purifying AAV8-FIX gene therapy produ...
AN ANTI-VEGF scFab ADENO-ASSOCIATED VIRUS (AAV) VECTOR AND USES THEREOF
Adeno-associated virus based viral vector system containing an expression cassette of VEGF neutralizing/ binding antibody, scFab fragment that is packaged in the optimized viral capsids for specific tissue tropism (i.e. different serotypes of...
AN ANTI-VEGF scFv ADENO-ASSOCIATED VIRUS (AAV) VECTOR AND USES THEREOF
Adeno-associated virus based viral vector system containing an expression cassette of VEGF neutralizing/ binding antibody, scFv that is packaged in the optimized viral capsids for specific tissue tropism (i.e. different serotypes of AAV). Such...
LACTATE MEDIUM SUPPLEMENTATION FOR CONTROL OF GLYCOSYLATION IN MAMMALIAN CELL CULTURE PROCESS
ABSTRACT
The present invention relates to a cell culture medium comprising addition of lactate and methods of using thereof. The present invention further relates to a method of producing a protein of interest in a la...
ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF MICRO-DYSTROPHIN TO TREAT MUSCULAR DYSTROPHY
rAAV based viral vector system containing an expression cassette of micro-dystrophin (abbreviated as µ-dys like MD1 and ?3990) that is packaged in the optimized viral capsids for muscle tissue tropism (i.e. different serotypes ...
“PURIFICATION OF MINOXIDIL SULFATE AND CRYSTALLINE FORM OF MINOXIDIL SULFATE”
ABSTRACT
The present invention relates to process for the purification of Minoxidil sulfate of formula I, crystalline form of Minoxidil sulfate and preparation of cryst...
“Palbociclib formulation.”
ABSTRACT
The present invention related to a stable pharmaceutical composition of palbociclib comprising palbociclib or its pharmaceutically acceptable salt thereof, a water soluble acid and one or more pharmaceutical acceptable excipients; wherein the said composition is prepared b...
ABSTRACT
NOVEL HIGH CONCENTRATION TRASTUZUMAB FORMULATION FOR SUBCUTANEOUS INJECTION
The invention provides highly concentrated, stable pharmaceutical formulation of Trastuzumab for subcutaneous injection. The said formulation comprise in addition to Trastuzumab, at least one buffering agent, such as e.g. histid...
ANTI - CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) FOR TREATING CANCER
The present invention relates to viral genome of recombinant LV particle wherein, the LV particle is packed with genes expressing chimeric antigen receptors against CD19 and the vector comprising such sequence. Further, the vector is used for the tre...
Gene therapy based administration of lentivirus vector for treating Hemoglobinopathies
The invention provides persistent expression of ß-globin gene by using cell and/or gene therapy based administration of nucleotide sequence encoding ß-globin gene to treat thalassemia and sickle cell anemia. Lentivirus (LV) based...
“An orodispersible pharmaceutical solid dosage form of rasagiline.”
ABSTRACT
The present invention relates to an orodispersible pharmaceutical solid dosage form comprising a therapeutically effective amount of rasagiline or a pharmaceutically acceptable salt thereof a pharmaceutically acceptable polymer suit...
“AN IMPROVED PROCESS FOR THE PREPARATION IBRUTINIB AND ITS AMORPHOUS FORM THEREOF”
ABSTRACT
The present invention relates to an improved process for the preparation of Ibrutinib of formula (I).
“Oral pharmaceutical composition of Arsenic Trioxide”
ABSTRACT
The present invention provides oral pharmaceutical composition comprising Arsenic trioxide and one or more pharmaceutically acceptable excipients for use in the treatment of acute promyelocytic leukemia and other cancers like acute myeloid leukemia...
“PROCESS FOR THE PREPARATION OF GLYCEROL PHENYLBUTYRATE”
ABSTRACT
The present invention relates to a process for the preparation of Glycerol phenylbutyrate of formula (I). The present invention also relates to novel intermediate compound of formula (II) as depicted below:
“PROCESS FOR THE PREPARATION OF GLYCEROL PHENYLBUTYRATE”
ABSTRACT
The present invention relates to the process for the preparation of Glycerol phenylbutyrate of formula (I). The present invention also relates to novel intermediate compound of formula (II) as depicted below:
An Improved PEG-GCSF Purification Process Having Dual UFDF
The invention relates to an improved process for the purification of proteins. More particularly, the invention pertains to a process for purification of Pegfilgrastim (PEG-GCSF). The invention further pertains to a purification process using ultrafiltrat...
“A stable ready to dilute injectable pharmaceutical formulation of Mitomycin”
ABSTRACT
The present invention relates to a stable ready to dilute (RTD) injectable pharmaceutical formulation of Mitomycin or a pharmaceutically acceptable salt thereof. The said formulation further comprises N, N - Dimethylacetamid...
“PREMIX OF PALBOCICLIB AND PROCESS FOR PREPARATION THEREOF”
ABSTRACT
The present invention relates to palbociclib - microcrystalline cellulose premix and process for its preparation. The present invention also provides a pharmaceutical composition comprising premix of palbociclib - microcrystalline cellulose pr...
“An orodispersible pharmaceutical dosage form of edoxaban.”
ABSTRACT
The present invention relates to an orodispersible pharmaceutical dosage form of edoxaban having overall improved characteristics, its process of manufacturing and its use as anticoagulant.
ABSTRACT
STABLE LYOPHILIZED FORMULATION OF AN ANTI-a4ß7 ANTIBODY
The invention provides stable lyophilized formulation of anti-a4ß7 antibody comprising buffer, sugar, bulking agent, viscosity reducer, antioxidant and surfactant.
“AN IMPROVED PROCESS FOR THE PREPARATION OF IBRUTINIB AND ITS AMORPHOUS FORM THEREOF”
ABSTRACT
The present invention relates to an improved process for the preparation of Ibrutinib and its amorphous form thereof. Ibrutinib is represented by the f...
“A stable extended release pharmaceutical composition of Clozapine”
ABSTRACT
The present invention provides to a stable extended release pharmaceutical composition of Clozapine and processes for preparation thereof, wherein the said pharmaceutical composition provides improved stability.
“An Extended release pharmaceutical composition of Clozapine”
ABSTRACT
The present invention provides an extended release pharmaceutical composition of Clozapine, wherein the said pharmaceutical composition is a reservoir type dosage form, and when dosed to a patient once daily achieves at steady state, AUC0-2...
“PROCESS FOR PREPARATION OF SAMIDORPHAN & ITS SALTS”
ABSTRACT
The present invention relates to an improved process for preparation of Samidorphan and its salts. The present invention also relates to novel intermediates, its preparation and their use for preparation of Samidorphan.
ABSTRACT
CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL DIRECTED AGAINST CD19, TO TREAT CD19+ B CELL MALIGNANCIES
The present invention relates to viral genome of recombinant LV particle wherein, the LV particle is packed with genes expressing chimeric antigen receptors against CD19 and the vector comprising such sequen...
ABSTRACT
STABLE LIQUID FORMULATION OF AN ANTI-a4ß7 ANTIBODY
The invention provides stable liquid formulation of anti-a4ß7 antibody comprising buffer, bulking agent/ stabilizer, viscosity reducer, antioxidant and surfactant, wherein the bulking agent/ stabilizer is sucrose, viscosity reducer is L-lysine HCl and a...
“Upadacitinib formulation.”
ABSTRACT
The present invention is related to pharmaceutical composition of upadacitinib comprising upadacitinib or its pharmaceutically acceptable salt thereof, release controlling polymer, pH modifier and one or more pharmaceutical acceptable excipient; wherein the release contro...
“AMORPHOUS ACALABRUTINIB MALEATE AND PROCESS FOR PREPARATION THEREOF”
ABSTRACT
The present invention relates to amorphous acalabrutinib maleate and process for preparation thereof. Acalabrutinib maleate is represented by following structural form...
“AN IMPROVED PROCESS FOR THE PREPARATION OF VIBEGRON”
ABSTRACT
The present invention relates to an improved process for the preparation of Vibegron, which is represented by the following structural formula (I).
...
“An orodispersible tablet of rivaroxaban.”
ABSTRACT
The present invention relates to an orodispersible tablet of rivaroxaban having overall improved characteristics, its process of manufacturing and its use as anticoagulant.
ABSTRACT
MULTI-COMPONENT BUFFER SYSTEM FOR PURIFICATION OF ANTIBODIES
The present invention relates to multi-component buffer system for purification of Antibodies. Specifically, present invention relates cation exchange chromatography process comprising multi-component buffer system and pH based elution for pur...
“AN IMPROVED PROCESS FOR THE PREPARATION OF VIBEGRON AND INTERMEDIATES THEREOF”
ABSTRACT
The present invention relates to an improved process for the preparation of Vibegron and intermediates thereof. Vibegron is represented by the following s...
CODON OPTIMIZED POLYNUCLEOTIDE ENCODING HUMAN FACTOR IX
The present invention relates to polynucleotide comprising codon optimized nucleotide encoding human Factor IX protein. The method of treatment of hemophilia by administering polynucleotide comprising codon optimized nucleotide encoding human Factor IX protei...
“IBRUTINIB METHYL VANILLATE CO-CRYSTAL AND PROCESS FOR PREPARATION THEREOF”
ABSTRACT
The present invention relates to Ibrutinib methyl vanillate co-crystal and process for preparation thereof. Ibrutinib is represented by the following structural ...
METHOD FOR CONJUGATION AND PURIFICATION OF ANTIBODY DRUG CONJUGATE
The present invention relates to the method for conjugation and purification of antibody drug conjugate wherein, the method controls drug to antibody ratio (DAR) and species distribution of antibody drug conjugate, such as Trastuzumab Emtansine. T...
“NOVEL POLYMORPH OF SAMIDORPHAN L-MALATE AND PROCESS FOR PREPARATION THEREOF”
ABSTRACT
The present invention relates to novel polymorph of Samidorphan L-malate and process for preparation thereof.
“Edoxaban formulation.”
ABSTRACT
The present invention is related to a pharmaceutical composition of edoxaban comprising edoxaban or its pharmaceutically acceptable salt thereof, water swelling additive and one or more pharmaceutical acceptable excipient, wherein the said formulation is devoid of sugar alcohol...
“PREMIX OF ACALABRUTINIB MALEATE AND PROCESS FOR PREPARATION THEREOF”
ABSTRACT
The present invention relates to premix of acalabrutinib maleate and process for preparation thereof. Acalabrutinib maleate is represented by following structural form...
“An orodispersible pharmaceutical solid dosage form of safinamide.”
ABSTRACT
The present invention is related to the orodispersible pharmaceutical composition of safinamide comprising safinamide or its pharmaceutically acceptable salt thereof, ion exchange resin and one or more pharmaceutical acceptable exci...
“DAPTOMYCIN FORMULATION.”
ABSTRACT
The present invention is related to a stable lyophilized pharmaceutical composition of daptomycin comprising daptomycin or its pharmaceutically acceptable salt thereof, meglumine, buffer and one or more pharmaceutical acceptable excipient, wherein the said lyophilized compo...
“PHARMACEUTICAL COMPOSITION OF DAPTOMYCIN.”
ABSTRACT
The present invention is related to a stable lyophilized pharmaceutical composition of daptomycin comprising daptomycin or its pharmaceutically acceptable salt thereof, stabilizer and one or more pharmaceutical acceptable excipient, wherein the said lyophi...
ABSTRACT
STABLE LIQUID CITRATE FREE FORMULATION OF AN ANTI-a4ß7 ANTIBODY
The invention provides stable liquid formulation of anti-a4ß7 antibody comprising buffer, viscosity reducer, and surfactant, wherein the viscosity reducer is L-arginine hydrochloride and surfactant is polysorbate 80, wherein formulation d...
“Pharmaceutical composition of Pirtobrutinib”
ABSTRACT
The present invention relates to the pharmaceutical composition comprising a solid dispersion containing Pirtobrutinib or a pharmaceutically acceptable salt, Hydroxypropyl methylcellulose phthalate, and one or more pharmaceutically acceptable excipients....
ABSTRACT
METHOD FOR IMPROVING GALACTOSYLATION PROFILE AND REDUCING OXIDIZED SPECIES IN PRODUCTION OF PEMBROLIZUMAB
The present invention provides a method of producing Pembrolizumab, comprising supplementing cell culture with methionine and MnCl2.
ABSTRACT
METHOD FOR REDUCING OXIDATION LEVELS IN VEDOLIZUMAB DURING CELL CULTURE PROCESS
The present invention provides a method of producing Vedolizumab, comprising supplementing cell culture with Methionine and thereby reducing the oxidation of cell culture.
ABSTRACT
NOVEL HIGH CONCENTRATION PHESGO FORMULATION
The present invention provides high concentration liquid pharmaceutical formulation of Phesgo comprising antibody, buffer, chelating agent, stabilizer/sugar, surfactant and hyaluronidase enzyme.
ABSTRACT
METHOD FOR MODULATION OF DARATUMUMAB GLYCOSYLATION PROFILE
The present invention provides a method for modulation of galactosylation and mannosylation level of Daratumumab by supplementation of manganese chloride and modulation of afucosylation level of Daratumumab by maintaining pCO2 with pH of cell cul...
ABSTRACT
METHOD FOR MODULATING AFUCOSYLATION LEVEL OF PERTUZUMAB
The present invention provides a method for modulation of afucosylation level of Pertuzumab by using pH shift of cell culture media, when cell culture achieves viable cell count (18-22) x 106 cells/mL.
ABSTRACT
METHOD FOR ENHANCING PRODUCTIVITY OF CLONES EXPRESSING PEMBROLIZUMAB
The present invention relates to a method for enhancing productivity of clones for high level of expression of gene of interest by super transfection.
ABSTRACT
STABLE LIQUID FORMULATION OF PEMBROLIZUMAB
The present invention provides stable liquid pharmaceutical formulation of pembrolizumab comprising antibody, buffering agent, stabilizer/bulking agent, and surfactant. The present liquid formulation is suitable for intravenous administration.
...
Registered Trademarks
[Class : 5] Veterinary Preparations.
[Class : 5] Veterinary Preparations.
[Class : 5] Pharmaceutical And Medicinal Preparations And Substances.
View +1469 more Brands for Intas Pharmaceuticals Limited.
Charges
04 September 2017
Standard Chartered Bank
184 Crore
28 December 2016
Axis Trustee Services Limited
3,218 Crore
28 December 2016
Axis Trustee Services Limited
1,845 Crore
25 June 1999
Icici Bank Limited
750 Crore
01 May 1998
Dena Bank
4 Crore
30 August 2012
Biotechnology Industry Research Assistance Council
18 Crore
21 March 2016
Citi Bank N.a.
115 Crore
14 June 2013
Idbi Trusteeship Services Limited
90 Crore
10 August 2010
Citibank N. A.
50 Crore
27 October 2010
Citi Bank N.a.
50 Crore
10 August 2010
Citi Bank N.a.
50 Crore
25 March 2010
Idbi Trusteeship Services Limited
105 Crore
06 November 2009
Idbi Trusteeship Services Limited
105 Crore
07 September 2009
Citi Bank N.a.
50 Crore
09 January 2009
State Bank Of India
273 Crore
27 March 2012
Indusind Bank Ltd.
25 Crore
24 June 2009
The Indusind Bank Limited.
7 Crore
17 July 2009
Idbi Bank Limited
40 Crore
21 February 2009
Indusind Bank Ltd.
30 Crore
06 September 2008
Axis Bank Limited
18 Crore
31 August 2006
Axis Bank Limited
7 Crore
30 June 2010
Hdfc Bank Limited
30 Crore
01 July 2009
Idbi Bank Limited
20 Crore
23 March 2012
Idbi Bank Limited
17 Crore
17 June 2008
Export Import Bank Of India
15 Crore
12 February 2007
Export - Import Bank Of India
22 Crore
01 June 2007
Icici Bank Limited
60 Crore
01 March 2011
Indusind Bank Ltd.
150 Crore
22 February 2012
Indusind Bank Ltd.
150 Crore
26 October 2007
Bnp Paribas
40 Crore
16 April 2008
Development Credit Bank Limited
3 Crore
24 March 2009
Tata Capital Limited
7 Crore
07 January 2008
Intas Pharmaceuticals Limited
3 Crore
07 February 2000
Gujarat State Financial Corporation
1 Crore
25 June 1997
Industrial Development Bank Of India
5 Crore
15 February 2006
Axis Bank Limited
20 Crore
21 December 2004
State Bank Of India
10 Crore
01 March 1996
Sbi
17 Crore
14 November 1996
State Bank Of India
17 Crore
25 June 1999
State Bank Of India
33 Lak
30 September 1997
State Bank Of India
19 Crore
30 September 1997
State Bank Of India
19 Crore
22 June 1996
Equatorial Private Limited.
4 Crore
21 April 1995
Equatorial Private Limited.
4 Crore
21 March 2001
Equatorial Private Limited.
1 Crore
21 March 1998
Equatorial Private Limited.
4 Crore
22 June 1996
Equatorial Private Limited.
4 Crore
22 June 1996
Equatorial Private Limited.
4 Crore
19 December 1997
Equatorial Private Limited.
4 Crore
08 September 2005
Abn Amro Bank N.v.
20 Crore
31 July 2002
Uti Bank Limited
20 Crore
02 January 2007
Rabo India Finance Limited
15 Crore
02 January 2007
Uti Bank Ltd
15 Crore
24 February 2004
Uti Bank Ltd
15 Crore
31 January 2004
State Bank Of India
13 Crore
18 June 1994
Gujarat Indl. Inve. Corporation Ltd
0
09 April 1997
Gujarat Indl. Inve. Corporation Ltd
0
01 August 1998
Gujarat Indl. Inve. Corporation Ltd
0
08 February 1995
Gujarat Indl. Inve. Corporation Ltd
0
09 September 2004
Icici Bank Ltd
20 Crore
25 February 2000
Icici Ltd
22 Crore
18 October 2002
Export Import Bank Of India
15 Crore
11 August 1995
Industrial Development Bank Of India
8 Crore
25 February 1997
Industrial Development Bank Of India
5 Crore
01 November 2001
Industrial Development Bank Of India
16 Crore
18 March 2002
State Bank Of India
95 Lak
04 April 2003
Icici Bank Ltd
13 Crore
03 November 2001
Export Import Bank Of India
1 Crore
30 March 2000
Export Import Bank Of India
3 Crore
25 November 1998
Export - Import Bank Of India
2 Crore
06 August 1999
Centurion Bank Ltd
6 Lak
04 August 1999
Industrial Development Bank Of India
7 Crore
13 July 1999
Industrial Development Bank Of India
5 Crore
03 November 2001
Export Import Bank Of India
3 Crore
03 December 1996
Exim Bank
4 Crore
21 October 1995
State Bank Of India
4 Crore
10 April 1995
State Bank Of India
4 Crore
30 August 1990
Dena Bank
1 Crore
08 January 1987
Dena Bank
11 Lak
08 January 1987
Dena Bank
36 Lak
07 December 1989
Dena Bank
5 Lak
30 August 1990
Dena Bank
5 Lak
28 December 2016
Others
0
25 June 1999
Others
0
21 March 2016
Citi Bank N.a.
0
12 February 2007
Export - Import Bank Of India
0
01 June 2007
Icici Bank Limited
0
07 January 2008
Intas Pharmaceuticals Limited
0
16 April 2008
Development Credit Bank Limited
0
17 June 2008
Export Import Bank Of India
0
21 February 2009
Indusind Bank Ltd.
0
24 June 2009
The Indusind Bank Limited.
0
17 July 2009
Idbi Bank Limited
0
06 November 2009
Idbi Trusteeship Services Limited
0
10 August 2010
Citi Bank N.a.
0
22 February 2012
Indusind Bank Ltd.
0
23 March 2012
Idbi Bank Limited
0
14 June 2013
Idbi Trusteeship Services Limited
0
15 February 2006
Axis Bank Limited
0
30 September 1997
State Bank Of India
0
11 August 1995
Industrial Development Bank Of India
0
25 February 1997
Industrial Development Bank Of India
0
25 November 1998
Export - Import Bank Of India
0
13 July 1999
Industrial Development Bank Of India
0
30 March 2000
Export Import Bank Of India
0
03 November 2001
Export Import Bank Of India
0
18 October 2002
Export Import Bank Of India
0
04 April 2003
Icici Bank Ltd
0
09 September 2004
Icici Bank Ltd
0
03 November 2001
Export Import Bank Of India
0
30 September 1997
State Bank Of India
0
25 June 1999
State Bank Of India
0
06 August 1999
Centurion Bank Ltd
0
08 September 2005
Abn Amro Bank N.v.
0
10 April 1995
State Bank Of India
0
22 June 1996
Equatorial Private Limited.
0
07 December 1989
Dena Bank
0
30 August 1990
Dena Bank
0
08 February 1995
Gujarat Indl. Inve. Corporation Ltd
0
19 December 1997
Equatorial Private Limited.
0
21 March 1998
Equatorial Private Limited.
0
01 August 1998
Gujarat Indl. Inve. Corporation Ltd
0
07 February 2000
Gujarat State Financial Corporation
0
22 June 1996
Equatorial Private Limited.
0
08 January 1987
Dena Bank
0
28 December 2016
Others
0
21 March 2001
Equatorial Private Limited.
0
31 August 2006
Axis Bank Limited
0
02 January 2007
Rabo India Finance Limited
0
02 January 2007
Uti Bank Ltd
0
26 October 2007
Bnp Paribas
0
06 September 2008
Axis Bank Limited
0
09 January 2009
State Bank Of India
0
24 March 2009
Tata Capital Limited
0
01 July 2009
Idbi Bank Limited
0
07 September 2009
Citi Bank N.a.
0
25 March 2010
Idbi Trusteeship Services Limited
0
30 June 2010
Hdfc Bank Limited
0
10 August 2010
Citibank N. A.
0
27 October 2010
Citi Bank N.a.
0
01 March 2011
Indusind Bank Ltd.
0
27 March 2012
Indusind Bank Ltd.
0
30 August 2012
Biotechnology Industry Research Assistance Council
0
21 October 1995
State Bank Of India
0
25 June 1997
Industrial Development Bank Of India
0
04 August 1999
Industrial Development Bank Of India
0
25 February 2000
Icici Ltd
0
01 November 2001
Industrial Development Bank Of India
0
18 March 2002
State Bank Of India
0
31 July 2002
Uti Bank Limited
0
31 January 2004
State Bank Of India
0
24 February 2004
Uti Bank Ltd
0
21 December 2004
State Bank Of India
0
01 March 1996
Sbi
0
14 November 1996
State Bank Of India
0
03 December 1996
Exim Bank
0
30 August 1990
Dena Bank
0
01 May 1998
Dena Bank
0
08 January 1987
Dena Bank
0
18 June 1994
Gujarat Indl. Inve. Corporation Ltd
0
21 April 1995
Equatorial Private Limited.
0
22 June 1996
Equatorial Private Limited.
0
09 April 1997
Gujarat Indl. Inve. Corporation Ltd
0
04 September 2017
Standard Chartered Bank
0
28 December 2016
Others
0
25 June 1999
Others
0
21 March 2016
Citi Bank N.a.
0
12 February 2007
Export - Import Bank Of India
0
01 June 2007
Icici Bank Limited
0
07 January 2008
Intas Pharmaceuticals Limited
0
16 April 2008
Development Credit Bank Limited
0
17 June 2008
Export Import Bank Of India
0
21 February 2009
Indusind Bank Ltd.
0
24 June 2009
The Indusind Bank Limited.
0
17 July 2009
Idbi Bank Limited
0
06 November 2009
Idbi Trusteeship Services Limited
0
10 August 2010
Citi Bank N.a.
0
22 February 2012
Indusind Bank Ltd.
0
23 March 2012
Idbi Bank Limited
0
14 June 2013
Idbi Trusteeship Services Limited
0
15 February 2006
Axis Bank Limited
0
30 September 1997
State Bank Of India
0
11 August 1995
Industrial Development Bank Of India
0
25 February 1997
Industrial Development Bank Of India
0
25 November 1998
Export - Import Bank Of India
0
13 July 1999
Industrial Development Bank Of India
0
30 March 2000
Export Import Bank Of India
0
03 November 2001
Export Import Bank Of India
0
18 October 2002
Export Import Bank Of India
0
04 April 2003
Icici Bank Ltd
0
09 September 2004
Icici Bank Ltd
0
03 November 2001
Export Import Bank Of India
0
30 September 1997
State Bank Of India
0
25 June 1999
State Bank Of India
0
06 August 1999
Centurion Bank Ltd
0
08 September 2005
Abn Amro Bank N.v.
0
10 April 1995
State Bank Of India
0
22 June 1996
Equatorial Private Limited.
0
07 December 1989
Dena Bank
0
30 August 1990
Dena Bank
0
08 February 1995
Gujarat Indl. Inve. Corporation Ltd
0
19 December 1997
Equatorial Private Limited.
0
21 March 1998
Equatorial Private Limited.
0
01 August 1998
Gujarat Indl. Inve. Corporation Ltd
0
07 February 2000
Gujarat State Financial Corporation
0
22 June 1996
Equatorial Private Limited.
0
08 January 1987
Dena Bank
0
28 December 2016
Others
0
21 March 2001
Equatorial Private Limited.
0
31 August 2006
Axis Bank Limited
0
02 January 2007
Rabo India Finance Limited
0
02 January 2007
Uti Bank Ltd
0
26 October 2007
Bnp Paribas
0
06 September 2008
Axis Bank Limited
0
09 January 2009
State Bank Of India
0
24 March 2009
Tata Capital Limited
0
01 July 2009
Idbi Bank Limited
0
07 September 2009
Citi Bank N.a.
0
25 March 2010
Idbi Trusteeship Services Limited
0
30 June 2010
Hdfc Bank Limited
0
10 August 2010
Citibank N. A.
0
27 October 2010
Citi Bank N.a.
0
01 March 2011
Indusind Bank Ltd.
0
27 March 2012
Indusind Bank Ltd.
0
30 August 2012
Biotechnology Industry Research Assistance Council
0
21 October 1995
State Bank Of India
0
25 June 1997
Industrial Development Bank Of India
0
04 August 1999
Industrial Development Bank Of India
0
25 February 2000
Icici Ltd
0
01 November 2001
Industrial Development Bank Of India
0
18 March 2002
State Bank Of India
0
31 July 2002
Uti Bank Limited
0
31 January 2004
State Bank Of India
0
24 February 2004
Uti Bank Ltd
0
21 December 2004
State Bank Of India
0
01 March 1996
Sbi
0
14 November 1996
State Bank Of India
0
03 December 1996
Exim Bank
0
30 August 1990
Dena Bank
0
01 May 1998
Dena Bank
0
08 January 1987
Dena Bank
0
18 June 1994
Gujarat Indl. Inve. Corporation Ltd
0
21 April 1995
Equatorial Private Limited.
0
22 June 1996
Equatorial Private Limited.
0
09 April 1997
Gujarat Indl. Inve. Corporation Ltd
0
04 September 2017
Standard Chartered Bank
0
Documents
Form PAS-6-06112020_signed
Optional Attachment-(1)-31102020
Form MSME FORM I-29102020_signed
Form MSME FORM I-28102020
Form MSME FORM I-28102020_signed
Form PAS-3-14102020_signed
Copy of Board or Shareholders? resolution-13102020
List of allottees. Attach separate list for each allotment (refer instruction kit for format).If not attached, then it shall be submitted separately in a CD.-13102020
Form MGT-7-10102020_signed
Copy of MGT-8-09102020
List of share holders, debenture holders;-09102020
Form AOC-4(XBRL)-01102020_signed
XBRL document in respect Consolidated financial statement-30092020
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-30092020
Form PAS-6-22092020_signed
Optional Attachment-(1)-16092020
Form CHG-4-25082020_signed
Letter of the charge holder stating that the amount has been satisfied-24082020
Form DPT-3-20082020-signed
Form MGT-14-27072020_signed
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-27072020
Form MGT-14-29052020-signed
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-28052020
Optional Attachment-(1)-28052020
Altered articles of association-28052020
Interest in other entities;-28052020
Declaration of the appointee director, Managing director, in Form No. DIR-2;-28052020
Optional Attachment-(1)-28052020
Form DIR-12-28052020_signed
